Abstract
OBJECTIVE: To evaluate the role of intravitreal bevacizumab (Avastin) in treatment of vitreous
hemorrhage due to proliferative diabetic retinopathy.
METHODS: This quasi-experimental trial was conducted at department of Ophthalmology Khairpur
Medical College, Khairpur Mir’s from January 2016 to June 2016. A number of 30 eyes of 30 patients
having vitreous hemorrhage were selected and given intravitreal injection of bevacizumab 1.25 mg/
0.05mi. Main outcome improvement in visual acuity with Snellen chart was observed at one week, four
week and three months.
RESULTS: Among 30 eyes visual acuity improved in 4 eyes (13.33%) in 1** week, 24 eyes 80%, improve
within four weeks, at the end of 3 months 25(83.33%) eyes improve in visual acuity, while 5 eyes
(16.66%) developed recurrent vitreous hemorrhage.
CONCLUSION: In our study the Intravitreal bevacizumab produced partial or complete resolution of
vitreous hemorrhage due to Proliferative Diabetic Retinopathy. Which is more useful in recent onset of
hemorrhage. It is my suggestion that it can be a fine alternative of surgery.
Attaullah Shah Bukhari, Aijaz Ahmed Shah, Shahid Jamal Siddiqui. (2018) Intravitreal Bevacizumab (Avastin) in Treatment of Vitreous Hemorrhage due to Proliferative Diabetic Retinopathy, Journal of Liaquat University of Medical and Health Sciences, Volume-17, Issue-2.
-
Views
607 -
Downloads
47
Article Details
Volume
Issue
Type
Language
